TRANSDERM, INC.

Company Information

Company Name
TRANSDERM, INC.
Address
2161 DELAWARE AVE
SANTA CRUZ, CA, 95060-5790
Phone
n/a
URL
n/a
DUNS
557564775
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,253,010.00
5
SBIR Phase II
$5,487,953.00
2
Chart code to be here

Award List

  1. Evaluation of siRNA uptake and functional activity in a human organotypic skin mo

    Amount: $340,859.00

    DESCRIPTION (provided by applicant): Although RNA interference offers high potential as a novel therapeutic approach for treating skin disorders, delivery concerns have hampered their progression to t ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Pachyonychia congenita clinical trial using therapeutic siRNAs

    Amount: $312,655.00

    DESCRIPTION (provided by applicant): ABSTRACT RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and s ...

    SBIR Phase I 2008 Department of Health and Human Services
  3. Development of topical rapamycin as a novel treatment for skin disorders

    Amount: $226,281.00

    DESCRIPTION (provided by applicant): In the decade and a half since the discovery of the underlying mutations in the keratin 5 (K5) and K14 genes in the skin disorder epidermolysis bullosa simplex (EB ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. In vivo imaging models for evaluating siRNA delivery to skin

    Amount: $148,215.00

    DESCRIPTION (provided by applicant): RNA interference offers the potential of a novel therapeutic approach for treating skin disorders. The technology to design, screen and identify potent, selective ...

    SBIR Phase I 2008 Department of Health and Human Services
  5. Development of siRNA delivery methodologies using in vivo imaging models

    Amount: $1,380,800.00

    DESCRIPTION (provided by applicant): RNA interference offers the potential of a novel therapeutic approach for treating skin disorders. The ability to design, screen and identify potent, selective an ...

    SBIR Phase II 2009 Department of Health and Human Services
  6. Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs

    Amount: $4,107,153.00

    DESCRIPTION (provided by applicant): RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and selective, ...

    SBIR Phase II 2011 Department of Health and Human Services
  7. Development of topical formulations for delivery of next generation mTOR inhibito

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): We discovered that the inducible keratins 6a and 6b, mutations in which can result in the skin and nail disorder pachyonychia congenita (PC), contain regulatory mo ...

    SBIR Phase I 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government